Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies
NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma
